Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

Table 3 Pharmacodynamics of currently used direct aging antivirals

Trade name	Compound	Efficacy	Toxicity
Zepatier	Elbasvir/grazoprevir	Effective regimen used for 12 wk against HCV genotype 1 and 4. Approved for patients with renal insufficiency and compensated cirrhosis. Fixed dose combination of 50 mg/100 mg once daily. Favourable safety profile with low discontinuation rates (< 5%)	Fatigue, headache, asthenia, nausea, rash, ALT/AST and ALP increase
Epclusa	Sofosbuvir/velpatasvir	Treatment for 12 wk highly effective in both treatment-experienced and treatment-naïve HCV pangenotypic patients	Fatigue, headache, nausea and insomnia. Combination therapy with ribavirin led to anaemia in over 10% of patients
Maviret	Glecaprevir/pibrentasvir	Pangenotypic highly effective regimen. Administered for 8 to 12 wk once daily at doses of 100 mg/40 mg. Naïve and experienced patients with or without cirrhosis	Headache, fatigue, nasopharyngitis and nausea
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	Pangenotypic, highly effective, licenced for patients in whom IFN/riba and DAAs failed	Headache, diarrhoea, fatigue, nausea and constipation

ALT: Alanine transaminase; AST: Aspartate transaminase; DAAs: Direct aging antivirals; HCV: Hepatitis C virus; IFN: Interferon.